For instance, palbociclib (a CDK4/6 inhibitor) in conjunction with letrozole (24.8 months) resulted in considerably longer progression-free survival than letrozole alone (14.5 months) in patients with previously untreated ER-positive, HER2-negative advanced breast cancer [3]. Here, CDK4 is linked to breast carcinoma.